[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053529":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":29,"locations":38,"responsibleParty":92,"collaborators":28,"id":94,"slug":28,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":95,"sex":101,"minAge":102,"maxAge":28,"enrollmentInfo":103,"targetDuration":28,"studyType":106,"phases":107,"briefSummary":109,"conditions":110,"keywords":28,"overallStatus":112,"whyStopped":28,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Verastem, Inc.","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"VS-7375 Monotherapy 2L\u002F3L","EXPERIMENTAL","2L\u002F3L VS-7375 dose",[13],"Drug: VS-7375",{"label":15,"type":10,"description":16,"interventionNames":17},"VS-7375 Monotherapy 2L\u002F3L Preferred Dose","2L\u002F3L Preferred VS-7375 dose",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"2L-4L with brain metastasis","2L-4L VS-7375 dose",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","VS-7375","Taken by mouth",[19,9,15],null,[30,35],{"name":31,"role":32,"phone":33,"phoneExt":28,"email":34},"Verastem Call Center","CONTACT","7812924204","VS-7375-202TrialSupport@verastem.com",{"name":36,"role":32,"phone":28,"phoneExt":28,"email":37},"Ting Wu, MD","VS-7375-202Medical@verastem.com",[39,59,76],{"facility":40,"status":28,"city":41,"state":42,"zip":43,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"START LA","Los Angeles","California","90025","United States",{"type":46,"coordinates":47},"Point",[48,49],-118.24368,34.05223,{"lat":49,"lon":48},[52,56],{"name":53,"role":32,"phone":54,"phoneExt":28,"email":55},"Hope Team Distribution List","4244651820","hopeteam@startresearch.com",{"name":57,"role":58,"phone":28,"phoneExt":28,"email":28},"Navid Hafez, MD","PRINCIPAL_INVESTIGATOR",{"facility":60,"status":28,"city":61,"state":62,"zip":63,"country":44,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"START New Jersey","East Brunswick","New Jersey","08816",{"type":46,"coordinates":65},[66,67],-74.41598,40.42788,{"lat":67,"lon":66},[70,74],{"name":71,"role":32,"phone":72,"phoneExt":28,"email":73},"Emily Lichtenstein","7324264750","emily.lichtenstein@startresearch.com",{"name":75,"role":58,"phone":28,"phoneExt":28,"email":28},"Bruno Fang, MD",{"facility":77,"status":28,"city":78,"state":79,"zip":80,"country":44,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"START Fort Worth","Fort Worth","Texas","76104",{"type":46,"coordinates":82},[83,84],-97.32085,32.72541,{"lat":84,"lon":83},[87,90],{"name":88,"role":32,"phone":89,"phoneExt":28,"email":55},"Hope Team","6823503010",{"name":91,"role":58,"phone":28,"phoneExt":28,"email":28},"Salwan Almutar, MD",{"type":93,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100053529",false,"NCT07659782","A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer","A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON\u002FOFF) Inhibitor, in Patients With Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)","TARGET-D 202","Inclusion Criteria:\n\n* Histopathology confirmed unresectable locally advanced or metastatic NSCLC\n* Measurable disease per RECIST 1.1\n* Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)\n* ECOG PS=0 or 1\n* Adequate organ function\n* Received prior treatment with a platinum-based chemotherapy regimen and an immune checkpoint inhibitor in the advanced, non-resectable setting.\n* Have documented disease progression during or following their most recent prior line of therapy.\n\nPatients with 2L\u002F3L on stable or preferred dose:\n\n* Received at least 1 and no more than 2 prior systemic lines of therapy for advanced (in the unresectable locally advanced or metastatic setting) NSCLC.\n\nPatients with 2L-4L with brain metastases:\n\n* Received at least 1 and no more than 3 prior systemic lines of therapy for advanced (in the unresectable locally advanced or metastatic setting) NSCLC.\n* Have asymptomatic and untreated brain metastases\n* At least 1 untreated measurable brain lesion per mRECIST v1.1 with a long axis ≥ 0.5 cm and ≤ 3 cm.\n\nExclusion Criteria:\n\n* Have any other documented co-existing common RAS mutation(s)\n* Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter\n* Major surgery within 4 weeks of first treatment dose\n* Radiation therapy (RT) within 1 week of first treatment dose\n* History of drug-induced Interstitial Lung Disease\n* Receipt of prior direct RAS inhibitor\n* Untreated or symptomatic CNS metastasis\n* Receipt of strong CYP3A4 inhibitor\u002Finducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter\n* Receipt of PPI or H2 blocker within 5 days\n* Inability to swallow oral medication\n* Other protocol-defined inclusion\u002Fexclusion criteria may apply","ALL","18 Years",{"count":104,"type":105},105,"ESTIMATED","INTERVENTIONAL",[108],"PHASE2","This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer",[111],"Non-Small Cell Lung Cancer","NOT_YET_RECRUITING","2026-07-09",{"date":115,"type":116},"2026-07-13","ACTUAL",{"date":118,"type":105},"2026-06",{"date":120,"type":105},"2028-12",{"name":5,"class":6},3]